BIOS Health

est. 2Y upside i

Series A

Neural interfaces to understand and use nerve data in medicine.

Rank

#2129

Sector

Neurotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

Insufficient data to assess equity upside.

Last updated: July 19, 2026

Bull (15%)0%

Cannot compute due to missing valuation. Optimistic scenario would require significant revenue acceleration and IPO exit.

Base (55%)0%

No valuation data; base case assumes current valuation is represented by total funding multiple.

Bear (30%)-100%

If equity is worth zero due to failure to raise or regulatory hurdles.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

Total funding of $26M creates significant preference overhang if valuation is low.

Dilution Risk

high

Series A in 2023, likely to raise another round within 24 months, diluting common.

Secondary Liquidity

none

No secondary market activity reported.

Questions to Ask at the Interview

Strategic questions based on BIOS Health's data — designed to show you've done your homework.

1
“How does the company plan to achieve revenue growth given the long regulatory timelines?”
2
“What is the current valuation and cap table?”
3
“What is the expected timeline to liquidity?”

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.